Yatharth Hospital & Trauma Care Services LtdNSE:YATHARTH
Current view Q4 2026
A proven engine: buy hospitals cheaply near Delhi, fill beds, raise the bill per bed. Sales up 36%, heading to 5,000 beds. New premium Gurugram hospital opens 2027; management delivers.
Latest exchange filings last 5 · 5 after Q4 2026
- 17 Sep ’26Board approved ₹3,150 crore preferential issue to Rasmalai Limited, raising authorised capital and calling EGM on 15 October 2026. ↗
- 17 Sep ’26Board approves ₹3,150 crore preferential issue to Rasmalai Limited; EGM on 15 Oct 2026 for approvals. ↗
- 17 Sep ’26Advent International to invest Rs 3,150 crore for 24.9% stake in Yatharth Hospitals. ↗
- 17 Sep ’26Board approved ₹3,150 crore preferential issue to Rasmalai Limited; EGM on 15 Oct 2026. ↗
- 14 Sep ’26Board meets September 17, 2026 to consider growth plans and fund raising via debt, rights issue, QIP or preferential allotment. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +47.4% | +6.9% | +36.2% | +41.2% |
| Operating profit | ▲ +40.4% | +8.1% | +32.1% | +35.7% |
| EPS | ▲ +22.6% | +4.7% | +21.9% | +10.4% |
| PAT | ▲ +15.4% | +4.7% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is PAT at +15.4%, which is ≥ 15% → Tier 2.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Average64/100
Growing fast — and the market has noticed. Profit per share grew 22% a year, and buyers now pay more for each rupee of it than they did a year ago. Some of the re-pricing has already happened.
₹1,100 → ₹2,201 needs the P/E at 66× — it is 60× today, and has ranged 34× to 97× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 100× — never traded above 97× in 5 years.
At ₹983 the price-tag on its earnings reaches the 54× it is being projected toward — the point where being cheap against that yardstick is used up.
Re-rated already, on growth that doesn't fully back it.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a mid-cap at ₹9,450 cr, so the odds of a re-rate are not fighting its own size.
Growth rate used: 21.9% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 23%.
How it compares with its rivals Healthcare · 6 of 30 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Yatharth Hospit. | ₹1,161 | 61.8× | ₹11,187 Cr | 12.4% | +11.9% | +52.3% |
| Apollo Hospitals | ₹8,830 | 60.3× | ₹1.27 L Cr | 17.4% | +34.2% | +20.6% |
| Max Healthcare | ₹1,053 | 68.4× | ₹1.02 L Cr | 14.7% | +4.9% | +16.7% |
| Manipal Health | ₹738 | 109.6× | ₹97,055 Cr | 12.1% | −7.9% | +38.1% |
| Fortis Health. | ₹895 | 63.4× | ₹67,599 Cr | 13.4% | +3.4% | +17.5% |
| Aster DM Quality | ₹764 | 184.5× | ₹66,574 Cr | 11.6% | −46.1% | +21.6% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | slightly narrower than 3 years earlier | operating margin 27% → 23% over 3 years |
|---|---|---|
| Did the profit turn into cash? | most of it, with some tied up | 98% last year, 66% over three · free cash flow −₹112 cr, positive in 2 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹264 cr — 0.15× its own equity (was 0.01×) |
| Is it being collected? | collection is steady | 113 days to collect, down 15 in a year · cash cycle −26 days |
| Who has been buying? | the promoters have been selling | promoters 55.8% (−5.8 in a year), 66.3% → 55.8% over 2.8 years · FIIs 5.6% (+1.3) · DIIs 10.8% (−2.7) · shareholders 50,113 → 96,264 |
| What does it earn on its capital? | earns a fair return on its capital | ROCE 12.4% · ROE 10.4% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company is expected to give good quarter
- Company has delivered good profit growth of 57.4% CAGR over last 5 years
- Company's working capital requirements have reduced from 102 days to 80.1 days
Against it
- Company has a low return on equity of 12.1% over last 3 years.
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.